Drugs / DTcP-Hib-MCV4
DTcP-Hib-MCV4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07203755 | Dec 2025 → Feb 2029 expected | haemophilus infectious disease, meningitis | CanSino Biologics Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-02-24 | CanSino Biologics Inc. | Regulatory CanSinoBIO Obtained Approval for Clinical Trials on DTcP-Hib-MCV4 Combined Vaccine cansinotech.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-02-24 | CanSino Biologics Inc. | CanSinoBIO Obtained Approval for Clinical Trials on DTcP-Hib-MCV4 Combined Vaccine cansinotech.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTcP-Hib-MCV4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07203755 ↗ |
| Known as | Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4) | “Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine...” NCT07203755 ↗ |
| Modality | Vaccine | “Combined Vaccine” NCT07203755 ↗ |